Aquigen Bio Sciences

In recent years, stringent scrutiny regarding the quality of pharmaceutical products has exposed the critical need for  advanced analytical methods  to identify and quantify impurities. Among these impurities, N-Nitroso compounds (NOCs) have gained significant attention, owing to their potential carcinogenicity even at trace levels. Regulatory agencies, including the US FDA and EMA, consistently refine their guidelines to ensure safer drug formulations for consumers. Hence, detecting N-nitroso impurities in active pharmaceutical ingredients (APIs), excipients, and drug products has become a high-priority challenge for manufacturers. Characterized by the presence of the nitroso functional group (-N=O), N-nitroso impurities can be inadvertently formed during manufacturing processes, commonly through reactions between nitrites and secondary or tertiary amines. Their detection and quantitation require sophisticated instrumentation, precise methodologies, and an in-depth understand...

In the pharmaceutical industry, the development and manufacture of Active Pharmaceutical Ingredients (APIs) require meticulous attention to quality control and impurity management. One particularly challenging class of impurities to address is the N-nitrosamines, also known as N-nitroso compounds. These impurities have garnered significant attention in recent years due to their potential carcinogenic properties, leading to increased regulatory scrutiny and the need for robust strategies to mitigate their formation during the API manufacturing process. As a leading  API impurity standard supplier in India , Aquigen Bio Sciences has extensive expertise in addressing the challenge of N-nitroso impurities. In this blog, we will explore the sources of N-nitroso impurities, discuss effective strategies for minimizing their formation, and highlight how Aquigen Bio Sciences can assist pharmaceutical companies in manufacturing APIs with low N-nitroso impurity levels. Sources of N-nitroso Im...